LABT · Lakewood-Amedex Biotherapeutics Inc.
$2.50
-0.26 (-9.42%)
At close · Sep 2
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has historically incurred recurring operating losses and negative operating cash flows and expects to continue to incur operating losses and consume cash as it executes its business plan. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed financial statements are issued. Because the Company will require additional financing within one year after the date these condensed financial statements are issued and such financing is not considered probable under the provisions of ASC 205-40, management has concluded that its plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.54M
Shares
2.37M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.76
Open$2.68
Day$2.53–2.86
Since split$1.85–3.97
Avg vol 30d3.4M
Short int56K · 2.4% float · 1.0d
Short vol52%
DataJun 2026–Sep 2026
Filing10-Q · Aug 14
Raw chart and full-history price indicators begin at the captured split on Jun 22, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jun 22, 2026.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Limited
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+10%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.37% of float · ▼ -55.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
6 holders — 13F breadth
Squeeze score
33
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
223%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
12.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+10%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.37% of float · ▼ -55.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
6 holders — 13F breadth
Price context
position in its range since split · 2026-06-22
Range low $2
Now $3 · 43%
Range high $4
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LABT
this stock
Lakewood-Amedex Biotherapeutics Inc.
|
$6.54M | — | — | — | 2.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +6.7% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +423.1% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
6
- % held
- 4.1%
- Net QoQ
- +97.8K sh
- Top holder
- Marex Group plc
Held
Float
Short & Settlement
Filings
Performance
Raw-price comparisons begin at the captured split on Jun 22, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LABT | +20.5% | +24.3% | — | +10.4% | — |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | +21.1% | +25.6% | — | +11.1% | — |